Candel Therapeutics, Inc. filings document a clinical-stage oncology company developing multimodal biological immunotherapies and reporting as a Nasdaq-listed issuer of common stock. Its proxy materials cover director elections, auditor ratification and annual-meeting voting matters, while Form 8-K reports furnish operating and financial results and research-and-development presentations.
Other filings disclose material agreements and capital-structure matters, including term-loan financing and facility lease amendments, along with clinical and regulatory disclosures tied to aglatimagene besadenovec and linoserpaturev. The filing record also reflects governance matters, shareholder voting mechanics and exhibit-based disclosures for key corporate actions.
Candel Therapeutics (CADL) reported a significant insider purchase by CEO and Director Paul Peter Tak on June 25, 2025. The transaction involved the acquisition of 42,826 shares at $4.67 per share through a registered direct offering, representing a total investment of approximately $200,000.
Following this transaction, Tak's direct beneficial ownership increased to 268,566 shares. The purchase was executed pursuant to a Securities Purchase Agreement dated June 23, 2025, demonstrating insider confidence in the company's prospects.
Key Transaction Details:
- Transaction Type: Direct Purchase (registered offering)
- Share Price: $4.67
- Total Shares Post-Transaction: 268,566
- Filing Date: June 28, 2025
- Transaction Form: Form 4 (Statement of Changes in Beneficial Ownership)
Paul B. Manning, Director of Candel Therapeutics (CADL), reported significant insider transactions on June 25, 2025. Manning acquired 1,070,663 shares at $4.67 per share through a registered direct offering, demonstrating substantial insider investment totaling approximately $5 million.
Following the transaction, Manning's beneficial ownership includes:
- 2,213,069 shares held indirectly through the Paul B. Manning Revocable Trust
- 1,303,752 shares held indirectly through BKB Growth Investments, LLC
- 1,681,000 shares held directly (jointly with spouse)
The total beneficial ownership amounts to 5,197,821 shares, indicating significant insider confidence in the company. The purchase was made pursuant to a Securities Purchase Agreement dated June 23, 2025, suggesting a planned strategic investment in the company's future.
Christopher Martell, Director of Candel Therapeutics (CADL), reported significant insider transactions and holdings on June 28, 2025:
Key Transaction: Acquired 111,349 shares of Common Stock at $4.67 per share on June 25, 2025, through a registered direct offering. These shares are held indirectly through his spouse.
Additional Indirect Holdings:
- 152,000 shares held through GTAM1 2012 LLC (trust where Martell serves as trustee)
- 283,514 shares held through GTAM1 2012 ADV LLC (where Martell serves as manager)
Total beneficial ownership across all indirect holdings amounts to 546,863 shares. The transaction was executed pursuant to a Securities Purchase Agreement dated June 23, 2025. Martell disclaims beneficial ownership of trust-held shares except for his pecuniary interest.
Charles Schoch, Chief Financial Officer of Candel Therapeutics (CADL), reported acquiring 5,353 shares of Common Stock on June 25, 2025, at a price of $4.67 per share through a registered direct offering. The transaction was executed pursuant to a Securities Purchase Agreement dated June 23, 2025.
Following this transaction, Schoch's direct beneficial ownership increased to 43,391 shares. The acquisition was made through a registered direct offering, indicating a structured investment in the company by its CFO.
- Transaction Type: Direct Purchase (Form Code: A)
- Transaction Value: Approximately $25,000
- Ownership Form: Direct
- No derivative securities were involved in this transaction
Director Nicoletta Loggia of Candel Therapeutics (NASDAQ: CADL) reported the acquisition of 2,141 shares of common stock on June 25, 2025. The shares were purchased at $4.67 per share through a registered direct offering, resulting in a total investment of approximately $10,000.
The transaction was executed pursuant to a Securities Purchase Agreement dated June 23, 2025. Following the reported transaction, Loggia directly owns 2,141 shares of Candel Therapeutics common stock.
Key Transaction Details:
- Transaction Type: Direct Purchase through Registered Offering
- Share Price: $4.67
- Total Shares Acquired: 2,141
- Ownership Type: Direct
- Filing Date: June 28, 2025
Insider Trading Alert: Gary J. Nabel, Director of Candel Therapeutics (NASDAQ: CADL), acquired 5,353 shares of common stock on June 25, 2025, at a price of $4.67 per share. The total transaction value amounts to approximately $25,000.
The shares were acquired through a registered direct offering pursuant to a Securities Purchase Agreement dated June 23, 2025. Following the transaction, Nabel directly owns 5,353 shares of Candel Therapeutics.
This Form 4 filing, submitted on June 28, 2025, represents a direct purchase of shares by a company insider, potentially signaling confidence in the company's prospects. The transaction was executed through an attorney-in-fact, Charles Schoch, who signed the filing on Nabel's behalf.
Candel Therapeutics Chief Scientific Officer Francesca Barone acquired 4,282 shares of common stock on June 25, 2025, through a registered direct offering at a price of $4.67 per share. The transaction was executed pursuant to a Securities Purchase Agreement dated June 23, 2025.
Following this acquisition, Barone now directly owns 100,809 shares of the company's common stock. The Form 4 filing indicates this was a direct ownership transaction, with no derivative securities involved.
- Transaction Type: Registered Direct Offering Purchase
- Total Transaction Value: $19,996.94
- Filing Status: Individual filing by reporting person
- Position: Chief Scientific Officer (Executive Officer)
Insider Trading Alert: Joseph C. Papa, Director of Candel Therapeutics (NASDAQ: CADL), acquired 64,239 shares of common stock on June 25, 2025, through a registered direct offering at $4.67 per share. The transaction was executed through the Joseph C. Papa Revocable Living Trust.
Key Transaction Details:
- Total shares acquired: 64,239 shares
- Purchase price: $4.67 per share
- Transaction value: approximately $300,000
- Post-transaction holdings: 64,239 shares (indirect) + 38,032 shares (direct)
The acquisition was made pursuant to a Securities Purchase Agreement dated June 23, 2025. The shares are held indirectly through a trust arrangement, with Papa serving as trustee. This insider purchase may signal management's confidence in the company's prospects.